Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a single day of brain radiation match five days?

NCT ID NCT05050929

NEW Symptom relief Sponsor: British Columbia Cancer Agency Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are testing whether a one-day course of targeted radiation works as well as the standard five-day course for people whose cancer has spread to the brain. The trial enrolls about 100 adults with brain metastases and a poor prognosis. Everyone receives precise, image-guided radiation aimed at all visible brain tumors, and the study compares how long patients live, how long they keep their daily functioning, and whether the tumors stay controlled.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
targeted radiation therapy to brain metastases, given either as a single high-dose treatment or split over five days
What this could lead to
If the one-day course works as well as the five-day course, patients with brain metastases could spend far less time traveling for treatment and start other care sooner.
What could go wrong
The trial is small and limited to patients with a poor prognosis, so results may not apply to everyone with brain metastases. A single high dose could also cause more short-term swelling or side effects than a split course.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients must fulfil all the following criteria to be eligible for admission to the study: * Age ≥ 18 * Pathological diagnosis of a non-hematopoietic malignancy * Brain metastases of any size * Any number of untreated or progressing, previously treated brain metastases that can all be contoured and targeted * Presence of extracranial disease * Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) ≤ 2.0 (https://brainmetgpa.com/) or Graded Prognostic Assessment ≤ 2.0 (Appendix I) * Able to complete the EuroQOL (EQ-5D-5L) questionnaire * Willing and able to have regular imaging follow up * Feasible to start protocol treatment within 14 calendar days of participant enrolment * Karnofsky Performance Score (KPS) ≥ 50 Exclusion Criteria Patients who fulfill any of the following criteria are not eligible for admission to the study: * Inability to have a brain MRI. * WBRT less than 3 months prior to randomization * Disseminated leptomeningeal carcinomatosis (limited pachymeningeal disease is permitted) * Multiple sclerosis * Neurologically declining despite corticosteroids * Appropriate for surgery or stereotactic radiosurgery * Germ cell and primary brain tumours * Systemic lupus erythematosis, scleroderma, or other connective tissue disorders not in remission * Any other serious intercurrent illness or medical condition judged by the local investigator to compromise the patient's safety, preclude safe administration of the planned protocol treatment, or prevent the patient from being managed according to the protocol guidelines * Pregnancy * Potentially fertile men or women of childbearing potential who are unwilling to employ highly effective contraception

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain metastases, adult

Contacts and locations

Locations

  • BC Cancer - Abbotsford

    Abbotsford British Columbia, British Columbia, Canada

  • BC Cancer - Kelowna

    Kelowna, British Columbia, V1Y5L3, Canada

  • BC Cancer - Prince George

    Prince George, British Columbia, V2M7E9, Canada

  • BC Cancer - Surrey

    Surrey, British Columbia, Canada

  • BC Cancer - Vancouver

    Vancouver, British Columbia, V5Z 4E6, Canada

  • BC Cancer - Victoria

    Victoria, British Columbia, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.